| |JUNE 20268TOP STORIESMAARGA MIND CARE LAUNCHES MATERNAL MENTAL HEALTH SUPPORT PROGRAMMEINDIA'S PHARMA EXPORTS TO US EXPECTED TO STAY MUTED AMID PRESSURETHERANYM BIOLOGICS LAUNCHES RS 1,200 CR TELANGANA BIOLOGICS HUBLUPIN, NATCO SECURE US FDA APPROVAL FOR CANCER DRUG INJECTIONMaarga Mind Care has launched an Integrated Maternal Mental Health Programme along with Maarga Divasa, an integrated day care programme aimed at supporting mothers through the emotional and psychological challenges that often come with pregnancy and early motherhood.The initiative comes at a time when maternal mental health is receiving growing attention as an important public health issue. While motherhood is often viewed as a joyful journey, many women quietly struggle with stress, anxiety, emotional exhaustion and depression during pregnancy or after childbirth.According to a major 2025 study published in The Lancet Psychiatry, which examined data from nearly two million women and girls across 90 countries, one in every 15 mothers develops major depressive disorder within the first year after giving birth. In countries like India, the numbers are even more concerning, with nearly one in five women estimated to experience postpartum depression. POIndia's pharmaceutical exports to the United States are expected to remain subdued this year, as multiple headwinds including pricing pressure in generics, policy uncertainty in the US healthcare system, and inventory correction cycles weigh on shipment volumes.The muted outlook comes at a time when the US continues to remain India's largest pharmaceutical export destination, accounting for nearly 30 percent of total outbound shipments.One of the key factors affecting export performance is the sharp price erosion in the US generics market. Intense competition among suppliers, coupled with aggressive cost optimization by US healthcare distributors, has significantly compressed realizations for Indian manufacturers. This has directly impacted margins for companies heavily dependent on the American market.Adding to the pressure is a high base effect. Industry data indicates that Indian pharma exports to the US in FY26 closed at approximately $9.47 billion, marking a 10 percent year-on-year decline. POTheraNym Biologics, a contract manufacturing arm of Aurobindo Pharma, has inaugurated a state-of-the-art biologics manufacturing facility in Telangana with an investment of Rs 1,200 crore, marking a significant expansion in India's advanced Pharmaceutical major Lupin Limited and its alliance partner Natco Pharma Limited have received approval from the United States Food and Drug Administration (FDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials. The approval covers Natco's Abbreviated New Drug Application (ANDA) for the product, which is bioequivalent to Halaven Injection, the reference listed drug marketed by Eisai Inc.pharmaceutical manufacturing capabilities.Located at Borpatla village in Sangareddy district, the facility is expected to support global pharmaceutical supply chains while reinforcing Telangana's position as a major biotechnology hub and life sciences centre.The launch of the new facility represents Aurobindo Pharma's strategic entry into biologics contract manufacturing, a high-growth segment focused on advanced therapies for complex diseases.The plant will manufacture biologic medicines used in the treatment of cancer and other life-threatening conditions, catering to domestic demand as well as exports to international markets, including the United States, subject to regulatory approvals. PO
< Page 7 | Page 9 >